ReviewhLife2025
Pancreatic cancer cachexia: A systemic consequence of multi-organ interactions.
Review in hLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer cachexia is a complex, multifactorial syndrome characterized by progressive wasting of skeletal muscle and adipose tissue, contributing to poor prognosis and high mortality in pancreatic cancer patients. While muscle and fat loss are the hallmark features, pancreatic cancer cachexia is increasingly recognized as a systemic disorder involving extensive metabolic and inflammatory disruptions across multiple organs. Tumor-derived cachexia-inducing factors play a central role in driving systemic inflammation, metabolic dysregulation, and neuroendocrine abnormalities, leading to anorexia, gut dysbiosis, cardiac dysfunction, and pancreatic exocrine and endocrine insufficiency. These multi-organ disturbances form a vicious cycle that accelerates disease progression and complicates clinical management. In this review, we provide a comprehensive overview of pancreatic cancer cachexia, including its definitions, classification, and heterogeneous clinical presentations. We further examine recent findings on the molecular mediators of cachexia and their role in inter-organ communication networks. Additionally, we highlight advances in experimental models that enable the dissection of pancreatic cancer cachexia pathophysiology, and discuss emerging mechanism-based therapeutic strategies aimed at disrupting the cachexia cycle. A deeper understanding of the systemic nature of pancreatic cancer cachexia and the crosstalk among affected organs may inform the development of multi-targeted interventions and hold promise for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.